Olmesartan

Olmesartan is a biphenylyltetrazole. Among its listed roles, it functions as a antihypertensive agent and an angiotensin receptor antagonist. Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, olmesartan’s physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. It is grouped under the following drug class(es): Angiotensin II Receptor Blockers (ARBs). Its therapeutic use is listed as antihypertensives and cardiovascular. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include omesartan, olmesartanum medoxomilum, Olmesartan Acid and Benicar;Olmetec. Its PubChem CID is 158781.